2010 Vol.28, N°5 - Suppl.61 - Table of contents

Methotrexate in rheumatic diseases

Guest Editors: J. Braun, T. Pincus, B. Cronstein

purchase complete issue

Editorial

CER4120
2010,28,5,Suppl.61
Pg. 0001-0002

Free to view

Methotrexate – the anchor drug – an introduction
T. Pincus, B. Cronstein, J. Braun

Review

CER4121
2010,28,5,Suppl.61
Pg. 0003-0008

Free to view

Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNFα
T.G. Benedek

CER3986
2010,28,5,Suppl.61
Pg. 0009-0012

Free to view

Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis
F.F. Coury, M.E. Weinblatt

CER4138
2010,28,5,Suppl.61
Pg. 0013-0020

Free to view

Increases in use of methotrexate since the 1980s
T. Sokka

CER3959
2010,28,5,Suppl.61
Pg. 0021-0023

Free to view

How does methotrexate suppress inflammation?
B. Cronstein

CER4006
2010,28,5,Suppl.61
Pg. 0024-0026

Free to view

Measuring methotrexate polyglutamates
S.M. Goodman

CER3988
2010,28,5,Suppl.61
Pg. 0027-0032

Free to view

Methotrexate bioavailability
E.N. Van Roon, M.A. Van De Laar

CER4132
2010,28,5,Suppl.61
Pg. 0033-0039

Free to view

Methotrexate pharmacogenetics in rheumatoid arthritis
R.R. Brinker, P. Ranganathan

CER4028
2010,28,5,Suppl.61
Pg. 0040-0045

Free to view

Methotrexate transport mechanisms: the basis for targeted drug delivery and ß-folate-receptor-specific treatment
C. Fiehn

CER4143
2010,28,5,Suppl.61
Pg. 0046-0051

Free to view

Optimal administration and dosage of methotrexate
J. Braun

CER4144
2010,28,5,Suppl.61
Pg. 0052-0057

Free to view

Drug combinations with methotrexate to treat rheumatoid arthritis
T. Rath, A. Rubbert

CER4017
2010,28,5,Suppl.61
Pg. 0058-0064

Free to view

Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis
R. Rau

CER4165
2010,28,5,Suppl.61
Pg. 0065-0067

Free to view

Long-term safety of methotrexate in the treatment of rheumatoid arthritis
Y. Yazici

CER4133
2010,28,5,Suppl.61
Pg. 0068-0079

Free to view

Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients
T. Pincus, V. Furer, T. Sokka

CER4010
2010,28,5,Suppl.61
Pg. 0080-0084

Free to view

Use of methotrexate in young patients with respect to the reproductive system
E. Gromnica-Ihle, K. Krueger

CER4140
2010,28,5,Suppl.61
Pg. 0085-0094

Free to view

Use of methotrexate in the elderly and in patients with compromised renal function
O. Morgacheva, D.E. Furst

CER3960
2010,28,5,Suppl.61
Pg. 0095-0101

Free to view

Side effects and management of side effects of methotrexate in rheumatoid arthritis
K. Albrecht, U. Mueller-Ladner

CER4142
2010,28,5,Suppl.61
Pg. 0102-0109

Free to view

Folate supplementation during methotrexate therapy for rheumatoid arthritis
S.L. Morgan, J.E. Baggott

CER4013
2010,28,5,Suppl.61
Pg. 0110-0113

Free to view

Perioperative use of methotrexate
F. Heldmann, J. Braun

CER4000
2010,28,5,Suppl.61
Pg. 0114-0116

Free to view

Methotrexate use and alcohol
S. Price, C. James, C. Deighton

CER4030
2010,28,5,Suppl.61
Pg. 0117-0121

Free to view

Use of methotrexate in undifferentiated arthritis
K. Visser, C.F. Allaart, T.W. Huizinga

CER4145
2010,28,5,Suppl.61
Pg. 0122-0127

Free to view

The use of methotrexate in children with rheumatic diseases
R. Gutierrez-Suarez, R. Burgos-Vargas

CER4122
2010,28,5,Suppl.61
Pg. 0128-0131

Free to view

Use of methotrexate in patients with ankylosing spondylitis
H. Haibel, J. Sieper

CER4124
2010,28,5,Suppl.61
Pg. 0132-0137

Free to view

Use of methotrexate in patients with psoriatic arthritis
A. Ceponis, A. Kavanaugh

CER4151
2010,28,5,Suppl.61
Pg. 0138-0144

Free to view

Use of methotrexate in patients with psoriasis
A. Kuhn, V. Ruland, N. Patsinakidis, T.A. Luger

CER4007
2010,28,5,Suppl.61
Pg. 0145-0150

Free to view

Use of methotrexate in patients with uveitis
A. Ali, J.T. Rosenbaum

CER4008
2010,28,5,Suppl.61
Pg. 0151-0155

Free to view

Use of methotrexate in patients with inflammatory bowel diseases
J.C. Preiss, M. Zeitz

CER4019
2010,28,5,Suppl.61
Pg. 0156-0159

Free to view

Use of methotrexate in patients with systemic lupus erythematosus (SLE) and primary Sjogren's syndrome
M. Winzer, M. Aringer

CER4011
2010,28,5,Suppl.61
Pg. 0160-0163

Free to view

Use of methotrexate in patients with scleroderma and mixed connective tissue disease
O. Kowal-Bielecka, O. Distler

CER4149
2010,28,5,Suppl.61
Pg. 0164-0167

Free to view

Use of methotrexate in inflammatory myopathies
C. Fendler, J. Braun

CER4148
2010,28,5,Suppl.61
Pg. 0168-0171

Free to view

Use of methotrexate in adult-onset Still´s disease
B. Manger, J. Rech, G. Schett

CER4147
2010,28,5,Suppl.61
Pg. 0172-0177

Free to view

Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica
C.M. Spies, G.-R. Burmester, F. Buttgereit

CER4150
2010,28,5,Suppl.61
Pg. 0178-0182

Free to view

Use of methotrexate in ANCA-associated vasculitides
E. Reinhold-Keller, K. De Groot

CER4020
2010,28,5,Suppl.61
Pg. 0183-0185

Free to view

Use of methotrexate in patients with sarcoidosis
U. Kiltz, J. Braun